Screener
Kymera Therapeutics KYMR Operating Lease Liabilities
Operating Lease Liabilities at other companies
Other financials
Where this comes from
Reported directly by Kymera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityNoncurrent.
The source filing: Kymera Therapeutics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 7:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333849
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Total current liabilities | $71,326 | $83,212 |
| Non-current liabilities | ||
| Deferred revenue, net of current portion | — | 11,440 |
| Operating lease liabilities, net of current portion | 64,022 | 67,034 |
| Finance lease liabilities, net of current portion | 840 | 1,462 |
| Total liabilities | $136,188 | $163,148 |
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 0 shares issued and outstanding as of June 30, 2026 and December 31, 2025 | — | — |
Item 1. Financial Statements.
FAQ
- What is Kymera Therapeutics's operating lease liabilities?
- Kymera Therapeutics (KYMR) reported operating lease liabilities of $64.02M in Q2 2026.
- How has Kymera Therapeutics's operating lease liabilities changed year-over-year?
- Kymera Therapeutics's operating lease liabilities decreased by 8.3% year-over-year, from $69.84M to $64.02M.
- What is the long-term trend for Kymera Therapeutics's operating lease liabilities?
- Over 5 years (2020 to 2025), Kymera Therapeutics's operating lease liabilities has grown at a 36.5% compound annual growth rate (CAGR), from $14.13M to $67.03M.
- What does operating lease liabilities mean?
- Long-term portion of operating lease obligations extending beyond one year, representing committed future rent payments.
Ask your AI about Kymera Therapeutics's operating lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude